Citations

Citations to this article as recorded by  

• Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer
  Lisa Richters, Oleg Gluz, Nana Weber-Lassalle, Matthias Christgen, Heinz Haverkamp, Sherko Kuemmel, Mohamad Kayali, Ronald E. Kates, Eva-Maria Grischke, Janine Altmüller, Helmut Forstbauer, Holger Thiele, Michael Braun, Mathias Warm, Anna Ossowski, Rachel
  JAMA Network Open.2025; 8(2): e2461639.     CrossRef
• Comprehensive analysis of HER2 Low Breast Cancer Response to Neoadjuvant Chemotherapy, a Retrospective Cohort Study
  Jie Lian, Ru Yao, Siyuan Pang, Xinyu Ren, Bo Pan, Yidong Zhou
  Clinical Breast Cancer.2025;[Epub]     CrossRef
• Clinicopathologic and Whole Exome Sequencing Analyzes of High-Grade Serous Carcinoma-Like Carcinoma of the Breast Reveal Unique Genetic Profile and Poor Clinical Outcome
  Wen-Yu Hsiao, Thi Truc Anh Nguyen, Wei Yang, Hu Yan, Zaibo Li, Linsheng Zhang, Jingjing Yang, Xiaoxian Li
  American Journal of Surgical Pathology.2025;[Epub]     CrossRef
• High frequency of the PIK3CA H1047L mutation in Indonesian breast cancer across molecular subtypes
  Yan Wisnu Prajoko, Didik Setyo Heriyanto, Bayu Tirta Dirja, Susanto Susanto, Vincent Lau, Andrew Nobiantoro Gunawan, Brigitta Natasya Halim, Nur Dina Amalina, Rashi Kalra
  PLOS One.2025; 20(5): e0322154.     CrossRef
• The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies
  Alexa E. Schmitz, Shirsa Udgata, Katherine A. Johnson, Dustin A. Deming
  Biomedicines.2025; 13(6): 1319.     CrossRef
• Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients
  Tatyana N. Sokolova, Grigory A. Yanus, Svetlana N. Aleksakhina, Yana V. Belysheva, Aleksandra P. Chernyakova, Yulia S. Zharnakova, Alisa S. Nikitina, Tatyana M. Stebneva, Aleksandr S. Martianov, Alla Yu. Goryainova, Mark I. Gluzman, Rashida V. Orlova, Ana
  Cancers.2025; 17(11): 1833.     CrossRef
• PIK3CA Mutations: Are They a Relevant Target in Adult Diffuse Gliomas?
  Ana Tomás, Marta Pojo
  International Journal of Molecular Sciences.2025; 26(11): 5276.     CrossRef
• Clinicopathological and prognostic analysis of PIK3CA mutated invasive breast cancer in Chinese women
  Juhang Chu, Luyao Huang, Yaru Wang, Mingping Qian
  Clinics.2025; 80: 100702.     CrossRef
• Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer
  Brian D. Lehmann, Vandana G. Abramson, E. Claire Dees, Payal D. Shah, Tarah J. Ballinger, Claudine Isaacs, Cesar A. Santa-Maria, Hanbing An, Paula I. Gonzalez-Ericsson, Melinda E. Sanders, Kimberly C. Newsom, Richard G. Abramson, Quanhu Sheng, Chih-Yuan H
  JAMA Oncology.2024; 10(2): 193.     CrossRef
• Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment
  Elena Zaikova, Brian Y. C. Cheng, Viviana Cerda, Esther Kong, Daniel Lai, Amy Lum, Cherie Bates, Wendie den Brok, Takako Kono, Sylvie Bourque, Angela Chan, Xioalan Feng, David Fenton, Anagha Gurjal, Nathalie Levasseur, Caroline Lohrisch, Sarah Roberts, Ta
  npj Breast Cancer.2024;[Epub]     CrossRef
• Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis
  Gabriela A. Martínez-Nava, Laura Keren Urbina-Jara, Saúl Lira-Albarrán, Henry L. Gómez, Erika Ruiz-García, María Tereza Nieto-Coronel, Rocio Ortiz-Lopez, Kenia Nadiezhda Martínez Villalba, Mariana Muñoz-Sánchez, Dione Aguilar, Liliana Gómez-Flores-Ramos,
  Diagnostics.2024; 14(3): 287.     CrossRef
• Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
  John M. Ketcham, Stephen J. Harwood, Ruth Aranda, Athenea N. Aloiau, Briana M. Bobek, David M. Briere, Aaron C. Burns, Kersti Caddell Haatveit, Andrew Calinisan, Jeffery Clarine, Adam Elliott, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Benjamin Jone
  Journal of Medicinal Chemistry.2024; 67(6): 4936.     CrossRef
• Prevalence and effect of PIK3CA H1047R somatic mutation among Indian head and neck cancer patients
  Arjita Ghosh, Anbalagan Moorthy
  Saudi Journal of Biological Sciences.2024; 31(8): 104029.     CrossRef
• Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review
  Ehsan Mehrtabar, Amirreza Khalaji, Mojtaba Pandeh, Aram Farhoudian, Nadia Shafiee, Atefe Shafiee, Fatemeh Ojaghlou, Parinaz Mahdavi, Mehdi Soleymani-Goloujeh
  Medical Oncology.2024;[Epub]     CrossRef
• Exploring the Inhibitory Efficacy of Resokaempferol and Tectochrysin on PI3Kα Protein by Combining DFT and Molecular Docking against Wild-Type and H1047R Mutant Forms
  Cristina Paraschiv, Steluța Gosav, Catalina Mercedes Burlacu, Mirela Praisler
  Inventions.2024; 9(5): 96.     CrossRef
• Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis
  Xingxin Wang, Xuhao Li, Tiantian Dong, Wenyan Yu, Zhixia Jia, Yi Hou, Jiguo Yang, Yuanxiang Liu
  International Journal of Surgery.2024; 110(12): 7962.     CrossRef
• Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
  Zhijun Li, Yiqun Han, Jiayu Wang, Binghe Xu
  Journal of Personalized Medicine.2023; 13(2): 190.     CrossRef
• Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
  Nadine S. van den Ende, Anh H. Nguyen, Agnes Jager, Marleen Kok, Reno Debets, Carolien H. M. van Deurzen
  International Journal of Molecular Sciences.2023; 24(3): 2969.     CrossRef
• A light-up fluorescence platform based DNA: RNA hybrid G-quadruplet for detecting single nucleotide variant of ctDNA and miRNA-21
  Gaihua Cao, Keyi Long, Yue Qiu, Lan Peng, Haiyan Han, Yongzhong Wang, Danqun Huo, Changjun Hou
  Talanta.2023; 257: 124373.     CrossRef
• Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
  Alexandre Bertucci, François Bertucci, Anthony Gonçalves
  Cancers.2023; 15(5): 1416.     CrossRef
• Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
  Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, Naoto T. Ueno
  Biomedicines.2023; 11(3): 735.     CrossRef
• Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation
  Bianca Lara Venâncio de Godoy, Marina Gobbe Moschetta-Pinheiro, Luiz Gustavo de Almeida Chuffa, Noam Falbel Pondé, Russel J. Reiter, Jucimara Colombo, Debora Aparecida Pires de Campos Zuccari
  Life Sciences.2023; 324: 121708.     CrossRef
• Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions
  Nicholas Mai, Nour Abuhadra, Komal Jhaveri
  Clinical Breast Cancer.2023; 23(8): 784.     CrossRef
• Role of epigenetics variation with focus on DNA methylation in triple-negative breast cancer patients
  GDeepthi Reddy, V Brahmaiah, BY Kavitha, Jayalatha Nethagani, ElizabethCaroline Palaparthi, RajasekharReddy Lebaka, G Deepika
  Archives of Medicine and Health Sciences.2023; 11(1): 96.     CrossRef
• RETRACTED: Potential Protective Role of Melatonin in Benign Mammary Cells Reprogrammed by Extracellular Vesicles from Malignant Cells
  Caroline Procópio de Oliveira, Barbara Frigieri, Heidge Fukumasu, Luiz Chuffa, Adriana Novais, Debora Zuccari
  Biomedicines.2023; 11(10): 2837.     CrossRef
• Role of Epigenetics Variation with Focus on DNA Methylation in Triple-Negative Breast Cancer Patients
  G. Deepthi Reddy, V. Brahmaiah, B. Y. Kavitha, Jayalatha Nethagani, Elizabeth Caroline Palaparthi, Rajasekhar Reddy Lebaka, G. Deepika
  Archives of Medicine and Health Sciences.2023; 11(1): 96.     CrossRef
• Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature
  Juan C. Hernandez-Prera, Daryoush Saeed-Vafa, Amin Heidarian, Kathleen Gewandter, Kristen Otto, Bruce M. Wenig
  Head and Neck Pathology.2022; 16(2): 416.     CrossRef
• PIK3CA Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness
  Cheila Brito, Ana Tomás, Ana Azevedo, Susana Esteves, Manuela Mafra, Lúcia Roque, Marta Pojo
  Clinical Medicine Insights: Oncology.2022;[Epub]     CrossRef
• Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer
  Menghao Dong, Benjie Shan, Xinghua Han, Xiaotian Zhao, Fufeng Wang, Liuqing Zhu, Qiuxiang Ou, Xiaopeng Ma, Yueyin Pan
  Frontiers in Oncology.2022;[Epub]     CrossRef
• Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
  Tatyana N. Sokolova, Tatyana I. Solov'eva, Svetlana N. Aleksakhina, Marina B. Bolieva, Viktor E. Goldberg, Marianna V. Kibisheva, Konstantin V. Menshikov, Dmitrii V. Ryazanov, Aleksandr V. Shkradyuk, Yana S. Chapko, Anna A. Shchukina, Idris M. Khabr
  Journal of Modern Oncology.2022; 24(1): 12.     CrossRef
• PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
  Liliana Ascione, Paola Zagami, Eleonora Nicolò, Edoardo Crimini, Giuseppe Curigliano, Carmen Criscitiello
  Journal of Personalized Medicine.2022; 12(11): 1793.     CrossRef
• Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
  Fokhrul Hossain, Samarpan Majumder, Justin David, Lucio Miele
  Cancers.2021; 13(15): 3739.     CrossRef
• Single-nucleotide variant of PIK3CA H1047R gene assay by CRISPR/Cas12a combined with rolling circle amplification
  Gaihua Cao, Xiaolong Chen, Yuanyi Deng, Fuping Nie, Yin Liu, Guoming Wang, Danqun Huo, Changjun Hou
  Analytica Chimica Acta.2021; 1182: 338943.     CrossRef
• Identification of effective natural PIK3CA H1047R inhibitors by computational study
  Naimeng Liu, Xinhui Wang, Xuan Li, Xiaye Lv, Haoqun Xie, Zhen Guo, Jing Wang, Gaojing Dou, Ye Du, Dong Song
  Aging.2021; 13(16): 20246.     CrossRef
• Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
  Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina M. Primeau, Jeremy Hoog, Jacqueline L. Mudd, Dennis A. Dean, Rajesh Patidar, Li Chen, Matthew A. Wyczalkowski, Reyka G. Jayasinghe,
  Nature Communications.2021;[Epub]     CrossRef
• Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
  Ana Julia Aguiar de Freitas, Rhafaela Lima Causin, Muriele Bertagna Varuzza, Cassio Murilo Trovo Hidalgo Filho, Vinicius Duval da Silva, Cristiano de Pádua Souza, Márcia Maria Chiquitelli Marques
  Cancers.2021; 13(21): 5477.     CrossRef
• Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis
  Wei Peng, Jian-Di Li, Jing-Jing Zeng, Xiao-Ping Zou, Deng Tang, Wei Tang, Min-Hua Rong, Ying Li, Wen-Bin Dai, Zhong-Qing Tang, Zhen-Bo Feng, Gang Chen
  Cancer Cell International.2020;[Epub]     CrossRef
• Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease
  Amal Qattan
  International Journal of Molecular Sciences.2020; 21(23): 8905.     CrossRef